Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio

Fineline Cube Dec 29, 2025
Company Deals

Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal

Fineline Cube Dec 29, 2025
Company Deals

Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing

Fineline Cube Dec 29, 2025
Company Deals

TJ Biopharma Partners with Zhejiang Lab to Develop AI‑Driven Ultra‑Long‑Acting Growth Hormone

Fineline Cube Dec 29, 2025
Company Deals

HBM Holdings and Lannacheng Biotech Forge Strategic Alliance for Next‑Generation RDCs in Precision Oncology

Fineline Cube Dec 29, 2025
Policy / Regulatory

NMPA Releases 2025 Priority Approval Directory for Eight High-End Medical Device Categories

Fineline Cube Dec 29, 2025
Company Drug

Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China

Fineline Cube Dec 29, 2025
Company Drug

BDgene Doses First Patient with BD920 CRISPR Gene Therapy for HPV-16 HSIL

Fineline Cube Dec 29, 2025
Company

Inscinstech Secures C-Series Financing for Biopharma Expansion

Fineline Cube Jan 19, 2025

Inscinstech Co., Ltd., a leading intelligent technology company based in Suzhou, has successfully completed a...

Company

Raytone Bio Completes Angel Round to Advance iSus® Platform

Fineline Cube Jan 18, 2025

Raytone Bio, a Shenzhen-based biopharmaceutical company, has announced the completion of a multi-million RMB Angel...

Company Drug

Aosaikang’s Limertinib Approved for EGFR T790M-Mutated NSCLC

Fineline Cube Jan 18, 2025

Jiangsu Aosaikang Pharmaceutical Co., Ltd (ASK Pharm, SHE: 002755) has recently received approval from the...

Company Drug

Johnson & Johnson Submits NDA for TAR-200 in High-Risk Bladder Cancer

Fineline Cube Jan 17, 2025

US-based Johnson & Johnson (J&J, NYSE: JNJ) has announced the initiation of the submission of...

Company Drug

Eli Lilly’s Omvoh Approved by FDA for Crohn’s Disease Treatment

Fineline Cube Jan 17, 2025

US major Eli Lilly and Company (NYSE: LLY) has announced receiving marketing approval from the...

Company Deals

IVIEW Therapeutics Secures Series A++ Funding for Ophthalmology Pipeline

Fineline Cube Jan 17, 2025

IVIEW Therapeutics Inc., an ophthalmology biotech operating out of the US and China, has reportedly...

Company Drug

Boehringer Ingelheim’s Iclepertin Fails to Meet Phase III Study Endpoints

Fineline Cube Jan 17, 2025

German giant Boehringer Ingelheim has disclosed negative top-line results from the Phase III CONNEX study...

Company Drug

Telix Pharmaceuticals’ TLX591-CDx Approved in Europe via Decentralized Procedure

Fineline Cube Jan 17, 2025

Australia-based Telix Pharmaceuticals Ltd (ASX: TLX) has announced that the marketing filing in Europe via...

Policy / Regulatory

NMPA Implements Regulatory Reforms for Drug and Medical Device Industries

Fineline Cube Jan 17, 2025

The National Medical Products Administration (NMPA) has released a notification regarding the implementation of the...

Company Deals Drug

Daiichi Sankyo Acquires Gatipotuzumab IP Rights for $132.5M

Fineline Cube Jan 17, 2025

Japan-based Daiichi Sankyo Company, Ltd (TYO: 4568) has announced an investment of USD 132.5 million...

Policy / Regulatory

NHSA Pushes for Real-Time Settlement Reform in Basic Medical Insurance

Fineline Cube Jan 17, 2025

The National Healthcare Security Administration (NHSA) has released a notification to promote the real-time settlement...

Company Deals

a16z Bio + Health Launches Biotech Ecosystem Venture Fund

Fineline Cube Jan 17, 2025

Andreessen Horowitz (a16z) Bio + Health has announced the establishment of the Biotech Ecosystem Venture...

Company Drug

Impact Therapeutics’ Senaparib Cleared by NMPA for Ovarian Cancer Therapy

Fineline Cube Jan 17, 2025

China-based Impact Therapeutics has announced receiving marketing clearance from the National Medical Products Administration (NMPA)...

Company

Siemens Lays Foundation for New Medical Equipment Base in Shenzhen

Fineline Cube Jan 17, 2025

Siemens (Shenzhen) Magnetic Resonance Co., Ltd., a wholly-owned subsidiary of Siemens Ltd., China, has officially...

Company Deals

Fujian Haixi Pharmaceuticals Files for Hong Kong IPO

Fineline Cube Jan 17, 2025

China-based Fujian Haixi Pharmaceuticals Co., Ltd., a commercial-stage innovative pharmaceutical company, has made an initial...

Company Drug

SciClone and Menarini Submit NDA for Vaborem in China

Fineline Cube Jan 17, 2025

China-based SciClone Pharmaceuticals Inc and its Italy-based strategic partner Menarini have announced the submission of...

Company Deals

Servier and Google Cloud Extend Partnership to Advance AI in Drug Development

Fineline Cube Jan 17, 2025

France-based Servier Group and US technology firm Google Cloud have announced an expansion to their...

Company Deals

Cathay Biotech Plans $901M Private Placement to Boost Bio-Based Materials

Fineline Cube Jan 17, 2025

Shanghai-based Cathay Biotech Inc. (SHA: 688065) has announced plans to raise RMB 6.6 billion (USD...

Company Deals

Simcere Licenses Fermion’s AI-Enabled Painkiller FZ002-037

Fineline Cube Jan 17, 2025

China-based Simcere Pharmaceutical Group Limited (HKG: 2096) has announced a licensing agreement with compatriot firm...

Company Medical Device

Boston Scientific’s FARAPULSE and WATCHMAN FLX Studies Show Positive Results

Fineline Cube Jan 17, 2025

US major Boston Scientific Corporation (NYSE: BSX) has announced the presentation of positive results from...

Posts pagination

1 … 161 162 163 … 602

Recent updates

  • Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio
  • Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal
  • Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing
  • Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China
  • BDgene Doses First Patient with BD920 CRISPR Gene Therapy for HPV-16 HSIL
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio

Company Deals

Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal

Company Deals

Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing

Company Drug

Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.